genetic testing companies need this tech and we are ahead of mkt, big game changer as the deals starting to come in at a quicker pace. Genetic testing space is going to explode as costs come down and need way to consolidate all the data. we are first to market. good luck everyone
One founder shareholder is Bio.be, a company owned by the Institute of Pathology and Genetics (IPG), the Belgian leader in genetic and pathological analyses, with a patient group coming from half the francophone hospitals in the country.
Deal flow is increasing. Company delivering on what it said in conference call. If you have not listened please do, doing what they said they would. This latest deal gets a foothold in europe.
$5 million cash on Balance Sheet; $6 million market capitalization, $0 Debt = $ 1 million of Enterprise Value
Need stock to be in better institutional hands = need one-on-one road shows to take place
Need a small capital raise with a healthcare fund = spending $1 million of cash per quarter - dilution is okay but only with the right partner!
Need more depth in management team = two deal people, one of which is Mika, and the other, has a big academic background. They've surprisingly done a pretty good job signing deals in the past year, but imagine the deals they could sign with a seasoned healthcare deal veteran (i.e. need a COO). FYI, Thomas Mika making $250+ in compensation = 25% of Enterprise Value
Need a CMO - someone to get the word out to physicians, healthcare service providers and patients
CLRX has a HUGE data opportunity, has signed some attractive partners (especially LIFE), is developing a major oncology network / editorial boards both vertically (cancer common) and horizontally (cancer specific)...all of which could make CLRX's knowledge database and services a key value driver with actionable intelligence at the point of care. Genetic testing is exploding...to figure out what to do as a healthcare service provider / physician will become increasingly complex and patient specific. Knowledge of which test to prescribe, which trial to enter, and which drug to take, all of which will be patient-specific based on their own DNA / Genome, is the future of medicine. It is ramping up quickly. CLRX has the opportunity to be a primary data provider to help this future happen. It's network alone is worth multiples of current valuation.
Adding to my position.
Roche buying clrx would be huge news-basicly another huge contract-they would just roll out CLRX life deal with Roche which almost give them a monopoly on thje sector
Next big deal they get from LIFE i think stock will gap to 7-8$ with such a small float- at 15$ the market is only 30million which is pocketchange for the big guys
Yup . Again net of cash its lunch money for someone. Sooner than later, as they have a big head start. I guess we will see, mkt will figure it out sometime.
CRM cloud king.
Just another tidbit. Continue adding deals, partnerships and someone is going to come knocking. Net of cash dirt cheap chance to get into hot sector. diagnostic cloud play. Just a matter of time imo
the same author been on fire- cbmx and today he did cali- got good track record